表面工程纳米架构:解决阿尔茨海默氏症疾病的不断发展的范式
Mansi Negi1, Etikala Amulya1, Vivek Phatale1
1Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
Life sciences
|October 21, 2024
概括
阿尔茨海默病 (AD) 影响着数百万人,目前的治疗只能提供症状缓解. 表面工程纳米载体在向药物输送方面表现有前途,克服了血脑屏障的挑战并提高了治疗效率.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 阿尔茨海默病 (AD) 是一种具有复杂病理生理学的渐进性神经退行性疾病,预计到2050年将影响全球1亿人.
- 目前的AD疗法仅提供症状缓解,并面临重大挑战,包括血脑屏障 (BBB),生物可用性差以及药物降解.
- 纳米载体 (NC) 具有潜力,但往往表现出非特异性向,导致外围毒性和有效性降低.
研究的目的:
- 审查AD病变发生过程中的分子信号通路.
- 探索纳米载体的表面功能化对AD管理的重要性.
- 讨论将这些先进疗法从实验室转化为工业的挑战和解决方案.
主要方法:
- 关于AD病原和基于纳米载体的治疗策略的综合文献综述.
- 对与阿尔茨海默病相关的分子信号通路的分析.
- 对用于纳米载体向和药物输送的表面工程技术的评估.
主要成果:
- 表面装饰的纳米载体与向配体增强药物输送到大脑,改善生物可用性和降低毒性.
- 功能化纳米载体有助于控制药物释放和更好地穿透BBB.
- 了解分子途径对于设计有效的向疗法至关重要.
结论:
- 纳米载体的表面工程是克服阿尔茨海默病治疗当前局限性的有希望的策略.
- 针对性交付系统对于改善阿尔茨海默病患者治疗结果和患者生活质量至关重要.
- 解决监管和临床障碍对于成功转化用于阿尔茨海默病的基于纳米载体的疗法至关重要.
更多相关视频
13:49Focused Ion Beam Lithography to Etch Nano-architectures into Microelectrodes
Published on: January 19, 2020
6.7K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.8K
相关概念视频
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
